Abstract. Secreted protein acidic and rich in cysteine-like 1 (SPARCL1), a member of extracelluar matrix glycoprotein, has been reported to be associated with various tumor types. The present study aimed to evaluate the prognostic value of SPARCL1 in patients with colorectal cancer. Tissue microarray blocks were constructed based on 79 patients who underwent radical surgery at the Kunshan First People's Hospital between 2008 and 2010. Thirty pairs of fresh-frozen tissues were also obtained for total protein extraction. The expression of SPARCL1 protein was analyzed using immunohistochemistry and western blotting analyses, and the association between overexpressed SPARCL1 and clinicopathological factors was evaluated. Survival analysis with Kaplan Meier curves and Cox regression analysis was used to analyze the prognostic value of SPARCL1. According to western blot analyses, SPARCL1 protein expression in colorectal tumors was significantly lower compared with corresponding normal tissues. The expression of SPARCL1 was markedly decreased from differentiation I to III, and the negative rate of SPARCL1 was higher at Duke's stage C compared with B. Though without any difference between 'positive' and 'negative' in overall survival, significantly higher survival in patients with positive SPARCL1 expression at Duke's stage B was detected in the present study. These results indicated that SPARCL1 may be a potential tumor suppressor gene and associated with good prognosis.
Introduction
Colorectal cancer (CRC), associated with high morbidity and mortality rates, has become one of the most common types of cancer (1) . Even with the improvement in diagnostic and therapeutic approaches, the prognosis of colorectal cancer remains poor primarily due to local recurrence, and distal metastases (2) . Therefore, the identification of novel reliable prognostic markers to predict the prognosis, and provide better and more suitable therapy for patients with colorectal cancer is warranted.
Secreted protein acidic and rich in cysteine-like 1 (SPARCL1), also known as SC1, Hevin and Mast 9, belongs to the SPARC-associated family of matricellular proteins (3, 4) . The SPARCL1 gene is localized at chromosome 4q22 and is expressed in various normal tissues, including the brain, heart, lung and lymphoid tissues (5, 6) . However, SPARCL1 is not expressed or expressed at a low level in various cancer types, except in hepatocellular carcinoma (5, 7) .
Recent studies have suggested that the most important function of SPARCL1 is modulating high endothelial cell adhesion to the basement membrane (3) . In addition, SPARCL1 is able to suppress tumor growth by prolonging the G 1 phase and inducing cell differentiation (8, 9) .
The prognostic role of SPARCL1 in patients with colorectal cancer appears to be controversial. Certain studies have suggested that elevated expression of SPARCL1 is associated with a better prognosis compared with low SPARCL1 expression, and with reduced odds ratios (ORs) of lymph node involvement and distant organ metastasis (9, 10) . Other studies have demonstrated that SPARCL1 is a negative regulator in the progression of CRC (11) . Notably, the expression of SPARCL1 has been observed to be increased from Dukes' stages A to B, but then decreased from Dukes' stages B to C and D (11) . The aim of the present study was to clarify the association between SPARCL1 expression and CRC progression and explore its prognostic value in patients with colorectal cancer.
Materials and methods
Tissue samples. The clinical and pathological data of 79 patients who were diagnosed with colorectal cancer at Dukes' stage B or C, and underwent radical surgery at Kunshan First People's Hospital (Kunshan, China) between January 2008 and December 2010 were reviewed. The mean age was 59.5 years, with 38 males and 41 females. None of the patients had received radiotherapy or chemotherapy prior to surgery. Thirty pairs of fresh-frozen colorectal tumors and matched normal tissues were also collected for total protein extraction and stored at -80˚C. Written informed consent was Institute of Biotechnology) were used to incubate the membranes for 1 h at 37˚C. Membranes were then detected using an Enhanced Chemiluminescence Detection system (Beyotime Institute of Biotechnology). The relative densities of proteins were quantified using ImageJ software (version 1.8.0; National Institutes of Health, Bethesda, MD, USA). The formula using to calculate the relative SPARCL1 expression was as follows: Gray value (SPARCL1)/gray value (β-actin).
Immunohistochemistry (IHC).
A mouse anti-human SPARCL1 polyclonal antibody (cat. no. ab107533; 1:200; Abcam, UK) was used as the primary antibody. A Streptavidin-HRP kit (CW2069A; CWBio, Beijing, China) was used for IHC according to the manufacturer's protocol. The slides were deparaffinized, rehydrated and heated in a microwave for 10-15 min in 10 mmol/l citrate buffer (Sigma-Aldrich; Merck KGaA, Darmstadt Germany). After the slides were cooled to room temperature, the slides were treated with reagent1 and reagent2 to block non-specific staining, and then treated with the primary antibody for 12 h. Slides were then incubated with reagent3 and reagent4 (anti-rabbit/mouse IgG) for 5 min, then treated with DAB and hematoxylin for visualization. Association between clinicopathological factors and SPARCL1 expression. A total of 79 patients with radically resected Duke's stage B or C tumors, were included in the present study. Of the 79 patients, 48 cases (60.76%) were negative expression for SPARCL1 ( Fig. 2A and B) and the other 31 (39.24%) were positive ( Fig. 2C and D ). Significant differences were identified in the SPARCL1 expression status in relation to differentiation and Duke's stages (P<0.05; Table I ), but no significant differences were identified among other parameters. The associations between clinicopathological features of patients with colorectal cancer and SPARCL1 expression are presented in Table I .
Results
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Survival analysis. Although no difference between positive and negative expression status was identified in overall survival analysis, and no significance in SPARCL1 expression was detected in the Cox regression analysis (P>0.05; Tables I   and II ; Fig. 4A ), immunohistochemical staining scores of patients who survived were significantly higher compared with those who succumbed (Fig. 3A) . In addition, scores of patients at Duke's stage B who survived were significantly higher compared with patients with stage C (Fig. 3) . Furthermore, the following Kaplan Meier curves demonstrated that positive expression of SPARCL1 was a potentially good indicator of Table I . Association between SPARCL1 expression and clinicopathological variables. 
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Discussion
In the present study, the expression of SPARCL1 protein was investigated in colorectal carcinoma tissues through western blot analysis and detected a significantly lower expression in colorectal tumors compared with in adjacent normal tissues.
The associations between SPARCL1 expression, clinicopathological factors and overall survival in patients with colorectal cancer were also analyzed. Since it was markedly decreased from differentiation I to III, it was hypothesized that the downregulation of SPARCL1 serves an essential role during the development and progression of colorectal cancer. Due to significantly higher survival in patients with positive SPARCL1 expression at Duke's stage B, SPARCL1 may be used as a potential biomarker for the prognosis of colorectal cancer. Despite a recent study demonstrated that SPARCL1 was a possible biomarker for the diagnosis of colorectal cancer, Zhang et al (11) reported that upregulated SPARCL1 was associated with poor survival. This conclusion was different the results of the present study, whereby SPARCL1 was an indicator of good prognosis at stage B, but not at C. In addition, another study reported that high SPARCL1 expression was associated with better prognosis in patients with rectal cancer with radiotherapy, but not in patients without radiotherapy (12) . Therefore, high SPARCL1 expression may indicate better prognosis in patients with colorectal cancer at early stage or with neoadjuvant therapy, implying that SPARCL1 is a valuable target, and a significant marker of diagnosis. In previous studies, downregulated SPARCL1 expression was demonstrated to be significantly associated with lymphatic metastasis and poor grade of breast cancer, gastric adenocarcinoma, prostate cancer, and lung adenocarcinoma (13) (14) (15) (16) . In hepatocellular carcinoma, the expression of SPARCL1 was elevated in tissues, but overexpression of Hevin and SPARC significantly delayed tumor growth in vivo (7) . Gene mutations, loss of heterozygosity (LOH), and aberrant promoter methylation were three common possible mechanisms of gene inactivation (17) . To the best of our knowledge, SPARCL1 gene was mapped to chromosome 4, which involves numerous hotspots for LOH in various tumor types, and a previous report, which included 10 paired tumor tissues with matched normal tissues, demonstrated that LOH may be responsible for the downregulation of SPARCL1 (8, 18) . However, following the transfection of SPARCL1 into colorectal cancer cells, including RKO and SW620 cells, overexpressed SPARCL1 protein significantly inhibited the growth, migration, and invasion of cancer cells (9) . The aforementioned studies support the results of the current study, indicating that SPARCL1 may be an indicator of good prognosis. However, the molecular signaling pathway underlying SPARCL1 interaction remains unclear.
SPARCL1, also known as 'SPARC-like 1', exhibits functions similar or opposite to SPARC to a certain extent (3, 4) . SPARCL1 is putatively counter-adhesive to dermal fibroblasts in a similar way to that of SPARC; but compared with SPARC, SPARCL1 does not significantly inhibit the proliferation of cells (19) . Likewise, high expression of SPARC and SPARCL1 may be two independent indicators of good prognosis in colorectal, and hepatocellular carcinomas (7, 9, 20) ; however, in other tumor types, their prognostic value appeared to be the opposite (18, (21) (22) (23) . In addition, the SLF (SPARC-like fragment), split from SPARCL1, similar to SPARC, may antagonize SPARCL1 and regulate synaptogenic activity (19) . However, no previous study reported the influence of SPARC expression on prognosis of SPARCL1. In the present study, the prognosis of SPARCL1 overexpression was discussed, but the value of SPARC was not evaluated. In spite of the result that elevated SPARCL1 expression in patients at Duke's stage B predicted a better prognosis, the level of SPARC expression may also influence the outcome.
In the present study, though with no significant value in Cox regression analysis, it was demonstrated that the level of SPARCL1 expression was associated with the overall survival of patients with Duke's stage B. Overexpression of SPARCL1 indicated the patients at Duke's stage B with a longer survival. This result further suggested that SPARCL1 is an 'early oncoprotein' in colorectal carcinoma. However, in view of the sample size with 79 patients, which was small, further studies should be performed to reveal the potential values of SPARCL1.
In conclusion, elevated SPARCL1 expression in patients with Duke's stage B colorectal cancer, presented an association with better prognosis. Herein, upregulated SPARCL1 may be a candidate biomarker of good prognosis for early colorectal carcinoma.
